A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
PHASE4CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
October 31, 2011
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG
erlotinib [Tarceva]
150 mg daily orally
Trial Locations (5)
20521
Turku
28500
Pori
70211
Kuopio
90029
Oulu
00290
Helsinki
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01287754 - A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations | Biotech Hunter | Biotech Hunter